Eledon Pharmaceuticals, Inc.
ELDN
$2.06
-$2.04-49.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.53% | -29.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.68% | -27.26% | |||
| Operating Income | -37.68% | 27.26% | |||
| Income Before Tax | -72.69% | 85.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -72.69% | 85.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -72.69% | 85.44% | |||
| EBIT | -37.68% | 27.26% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -72.68% | 85.91% | |||
| Normalized Basic EPS | -72.81% | 86.70% | |||
| EPS Diluted | -72.68% | 85.91% | |||
| Normalized Diluted EPS | -72.81% | 86.70% | |||
| Average Basic Shares Outstanding | 0.04% | 10.42% | |||
| Average Diluted Shares Outstanding | 0.04% | 10.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||